Thrombocytosis in EPO-treated dialysis patients may be mediated by EPO rather than iron deficiency.
Vaziri
Nosratola D
ND
D018798:Anemia, Iron-Deficiency / Q000097:blood / Q000150:complications*; D000818:Animals; D049109:Cell Proliferation; D004921:Erythropoietin / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy*; D008533:Megakaryocytes / Q000187:drug effects / Q000473:pathology; D010974:Platelet Aggregation / Q000502:physiology; D011994:Recombinant Proteins; D006435:Renal Dialysis / Q000009:adverse effects / Q000379:methods*; D013922:Thrombocytosis / Q000097:blood / Q000139:chemically induced* / Q000473:pathology
D011994:Recombinant Proteins; D004921:Erythropoietin